Comparative Pharmacology
Head-to-head clinical analysis: BROMPHERIL versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHERIL versus PROMETHAZINE DM.
BROMPHERIL vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheril is a mu-opioid receptor agonist with additional sigma-1 receptor antagonism, producing analgesic effects and modulating neuropathic pain.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
In adults, the usual dose is 1-2 mg/kg intravenously every 4-6 hours as needed. Alternatively, 5 mg can be administered intramuscularly or subcutaneously every 4 hours.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal half-life 2.5-4 hours; prolonged in renal impairment (up to 12 hours in severe cases).
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Primarily renal (60-70% as unchanged drug); 15-20% fecal via biliary elimination; minor metabolic clearance.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic